Login to Your Account

Diamyd's Shares Tumble on Phase II Gene Therapy Miss

By Cormac Sheridan
Staff Writer

Thursday, July 5, 2012
Shares in Diamyd Medical AB dropped 30 percent Tuesday on news that its gene therapy treatment for cancer pain missed the primary endpoint in a Phase II placebo-controlled trial.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription